We’re excited to share Perfetto v59.1! This release brings traces that survive device reboots on Android, a much friendlier Trace Processor command line (rustc-style SQL errors, markdown output and a ...

Forbes contributors publish independent expert analyses and insights. I cover the intersection of people, risk, leadership and performance. This voice experience is generated by AI. Learn more. This ...

The last time I spoke about Recursion Pharmaceuticals (RXRX), it was with a Seeking Alpha article entitled "Recursion: "Hold" Rating Based On Initial REC-4881 FAP Treatment Data." With respect to this ...

Salt Lake City, UT, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and ...

The Wolverine peptide stack combines two synthetic peptides (BPC-157 and TB-500) marketed for muscle repair and healing, but it isn’t approved by the FDA and hasn’t been tested in humans for safety or ...

Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. The rise of generative AI and agentic AI, with AI coding tools capabilities, has created a ...

Sept 24 (Reuters) - A consortium backed by BlackRock (BLK.N), opens new tab and IFM Investors is in exclusive talks to buy Stack Infrastructure's Asia Pacific data center portfolio for ‌up to $25 ...

OpenAI released a set of proposals for safety and security in the development of frontier AI in a blog post. The ChatGPT maker focused on alignment research and recursive self-improvement, or RSI.

How do you get from a chatbot that sometimes makes things up to a machine that humans might struggle to control? There are several steps in that argument, and plenty of uncertainty. But an idea known ...

Recursion Pharmaceuticals, Inc. remains a Hold as competitive advances and slow revenue growth challenge its AI-driven drug discovery ambitions. RXRX's partnerships, notably with Genentech/Roche and ...